DVA - DaVita Inc.
Greg Abel may have taken over as CEO, but he's not the only one making key investment decisions at Berkshire Hathaway. Berkshire's positions in DaVita and SiriusXM, reportedly selected by Ted Weschler, who manages a portion of the portfolio, have outperformed so far in 2026.
DaVita HealthCare (DVA) reached $230.72 at the closing of the latest trading day, reflecting a -1.53% change compared to its last close.
ADM, CASY, DVA, CVS and BEN top a list of five non-AI S&P 500 stocks that surged more than 30% in 1H 2026 and still show momentum for 2H.
On July 02, 2026, DaVita Inc (DVA) shares rose 3.0% to a current price of $234.91. The stock has experienced significant price appreciation recently, with a 10.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
DVA, FIVE, and PBI it to the Zacks Rank #1 (Strong Buy) growth stocks list on July 2, 2026.
DVA is advancing kidney care through IKC expansion, CMS CKCC progress and AI-driven dialysis scheduling improvements.
DVA, FIVE, and PBI it to the Zacks Rank #1 (Strong Buy) growth stocks list on June 30, 2026.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
In the most recent trading session, DaVita HealthCare (DVA) closed at $217.04, indicating a +1.72% shift from the previous trading day.
Analysts don't like to put "sell" ratings on S&P 500 stocks. So the fact they're willing to do it with some is worth your attention.
LYB, HRB and DVA made it to the Zacks Rank #1 (Strong Buy) growth stocks list on June 26th, 2026.
The latest trading day saw DaVita HealthCare (DVA) settling at $213.04, representing a +1% change from its previous close.
DVA is expanding kidney care through outpatient, home-centered and value-based programs while investing in AI-enabled scheduling.
HRB, DVA and PBI made it to the Zacks Rank #1 (Strong Buy) growth stocks list on June 24th, 2026.
DaVita and Fresenius Medical Care are taking different paths in kidney care, but which stock offers stronger upside now? Let's dive in.
Medical stocks like Centene, DaVita and BrightSpring could rally as SpaceX IPO-fueled market optimism lifts broader sector sentiment.
HRB, DVA and PBI made it to the Zacks Rank #1 (Strong Buy) growth stocks list on June 22nd, 2026.
DaVita HealthCare (DVA) closed the most recent trading day at $207.91, moving 1.27% from the previous trading session.
Investors target stocks that have been on a bullish run. Stocks like MUSA, DVA, HPE and VSH are seeing price strength, and the momentum is likely to continue.